共 29 条
- [11] Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial (vol 22, pg 1250, 2021) [J]. LANCET ONCOLOGY, 2022, 23 (06): : E249 - E249
- [12] Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial (vol 22, pg 1250, 2021) [J]. LANCET ONCOLOGY, 2022, 23 (05): : E207 - E207
- [13] KLF5 downregulation desensitizes castration-resistant prostate cancer cells to docetaxel by increasing BECN1 expression and inducing cell autophagy (vol 9, pg 5464, 2019) [J]. THERANOSTICS, 2023, 13 (09): : 2962 - 2963
- [15] Combination simvastatin and metformin induces G1-phase cell cycle arrest and Ripk1-and Ripk3-dependent necrosis in C4-2B osseous metastatic castration-resistant prostate cancer cells [J]. CELL DEATH & DISEASE, 2014, 5 : e1536 - e1536
- [16] Combination simvastatin and metformin induces G1-phase cell cycle arrest and Ripk1- and Ripk3-dependent necrosis in C4-2B osseous metastatic castration-resistant prostate cancer cells [J]. Cell Death & Disease, 2014, 5 : e1536 - e1536
- [18] MicroRNA-148b Acts as a Tumor Suppressor in Cervical Cancer by Inducing G1/S-Phase Cell Cycle Arrest and Apoptosis in a Caspase-3-Dependent Manner [J]. MEDICAL SCIENCE MONITOR, 2016, 22 : 2809 - 2815